title: [Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
abstract: Bevacizumabis a humanized anti-vascular endothelial growth factor(VEGF)monoclonal antibody that inhibits angiogenesis. In this study, we examined bevacizumab plus paclitaxel therapy for metastatic breast cancer. We divided 20 patients into hormone-positive(estrogen receptor[ER]+or progesterone receptor[PgR]+)and hormone-negative groups(ER-and PgR-). The average number of bevacizumab plus paclitaxel therapy cycles was 3.35(range, 1-14). The response rates for the hormone-positive and hormone-negative groups were 6.6% and 20%, respectively. Although the response rate was low in all cases, one patient who received first-line bevacizumab plus paclitaxel therapy was evaluated PR.
authors.affiliation: Division of Breast and Endocrine Surgery, Dept. of Biomedical Sciences, Nihon University School of Medicine.
authors.forename: Shuhei
authors.initials: S
authors.lastname: Suzuki
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sakurai
authors.forename: Saki
authors.initials: S
authors.lastname: Nagashima
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Hara
authors.forename: Sadao
authors.initials: S
authors.lastname: Amano
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Enomoto
authors.forename: Makoto
authors.initials: M
authors.lastname: Makishima
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage; D012008:Recurrence
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel